Industry Newsnovel drugsbiopharmaceuticalsnmpareimbursement policy
China Expands Novel-Drug Approvals And Reimbursement
|
7.3
In 2025 China's National Medical Products Administration approved a record 76 innovative drugs, officials said, up from 48 in 2024. The approvals, combined with regulatory reforms since 2015 and the addition of new therapies to the 2026 national reimbursement list, have lowered patient costs and driven $135.7 billion in out-licensing deals in 2025, signaling rising domestic biopharma influence globally.
Scoring Rationale
Record approvals, regulatory reform and large out‑licensing illustrate substantial industry impact; limited AI/DS relevance reduces cross-domain effect.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
